Get started
Author

Ilenia Savinelli

Observed name: I. Savinelli
Institution: University of Turin
Observed institution: University of Turin
ORCID: 0009-0000-1396-1845
Observed ORCID: 0009-0000-1396-1845
OpenAlex ID: A5115989302
Oncogenic mutant KRAS inhibition through oxidation at cysteine 118
2025 · Maximilian Kramer‐Drauberg, Ettore Petrini, et al. · Molecular Oncology · 4
PDF
EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al. · Cancer Discovery · 2
PDF
Data from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al. · 1
Suppl. Figure 10 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al.
Suppl. Figure 3 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al.
Suppl. Figure 2 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al.
Suppl. Figure 4 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al.
Suppl. Figure 6 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al.
Suppl. Table 1 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al.
Suppl. Figure 1 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al.
Suppl. Figure 5 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al.
Suppl. Figure 9 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al.
Suppl. Figure 7 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al.
Suppl. Figure 11 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al.
Suppl. Figure 8 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
2026 · Pietro Scaparone, Alessia Mira, et al.
P3.03.17 Intermittent Caloric Restriction Synergies With KRAS(OFF) Inhibitors in Preclinical Models of KRASG12C Lung Adenocarcinoma
2025 · E. Garbo, P. Scaparone, et al. · Journal of Thoracic Oncology
Author response for "Oncogenic mutant KRAS inhibition through oxidation at cysteine 118"
2024 · Maximilian Kramer‐Drauberg, Ettore Petrini, et al. · Publons reviews and discussion
Works count: 17
Citation count: 7
H-index: 2
I10-index:
Year
Topic
Type